Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Gynecologic Oncology Physician in San Diego, CA
NPI: 1144486929Primary Employer
UCSD Medical Group
health.ucsd.edu
HQ Phone
Get M.D Ramez's Phone Numberphone_androidMobile
Get M.D Ramez's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2008 - 2025
American Board of Obstetrics and Gynecology
Obstetrics & Gynecology
American Board of Obstetrics and Gynecology
Gynecologic Oncology
UC San Diego School of Medicine
medschool.ucsd.edu
Medical School
Until 2006
University of California (Irvine)
Fellowship • Gynecologic Oncology
2010 - 2014
University of California (San Diego) Medical Center
Residency • Obstetrics and Gynecology
2006 - 2010
David Geffen School of Medicine at UCLA
medschool.ucla.edu
B.S. • Microbiology
1998 - 2002
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 80 | 153 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 69 | 211 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 21 | 38 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 15 | 15 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 13 | 14 |
Mechanisms of apoptosis induction by flavokawain B in a uterine leiomyosarcoma cell line.
Authors: Eskander R, Sakai T, Guo Y, Zi X, Hoang BH, Randall-Whitis LM
Publication Date: 2011-05
Improved Prognosis of Treatment Failure in Cervical Cancer with Nontumor PET/CT Radiomics.
Authors: Carl Hoh, Loren Mell, Cheryl Saenz, Catheryn Yashar, Michael Mchale, Sebastian Obrzut, Aaron Simon, Casey Williamson, Jyoti Mayadev
Journal: J Nucl Med
Publication Date: 2021-10-28
The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients.
Authors: Judith Wolf
Publication Date: 2016-04-08
Lead Sponsor: CanariaBio Inc.
Collaborators: Iqvia Pty Ltd, Gynecologic Oncology Group
Intervention / Treatment: DRUG: Carboplatin, BIOLOGICAL: Placebo, DRUG: Paclitaxel, BIOLOGICAL: Oregovomab
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology, Canadian Cancer Trials Group
Intervention / Treatment: DRUG: Carboplatin, OTHER: Questionnaire Administration, BIOLOGICAL: Pembrolizumab, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel, OTHER: Placebo Administration, PROCEDURE: Computed Tomography
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Computed Tomography, DRUG: Tazemetostat